47,617 Shares in Roivant Sciences Ltd. $ROIV Purchased by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,617 shares of the company’s stock, valued at approximately $1,029,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its position in Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after purchasing an additional 500 shares during the period. Bessemer Group Inc. raised its position in Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Allworth Financial LP raised its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Fifth Third Bancorp raised its position in Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock worth $94,000 after purchasing an additional 588 shares during the period. Finally, Utah Retirement Systems raised its position in Roivant Sciences by 3.0% in the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after purchasing an additional 600 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $29.50 on Friday. The company has a market capitalization of $21.11 billion, a P/E ratio of -25.21 and a beta of 1.14. The company’s 50-day simple moving average is $28.41 and its two-hundred day simple moving average is $24.64. Roivant Sciences Ltd. has a one year low of $10.58 and a one year high of $30.33.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the transaction, the chief executive officer directly owned 16,736,116 shares in the company, valued at $488,025,142.56. This represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of the company’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,745,173 shares of company stock worth $103,639,917. 10.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of recent analyst reports. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Roivant Sciences in a research report on Friday, May 8th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Piper Sandler upped their target price on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $30.55.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.